Remove Engineering Remove Licensing Remove Virus
article thumbnail

FDA to ask Sarepta to stop shipping Duchenne gene therapy

BioPharma Drive: Drug Pricing

Published July 18, 2025 • Updated 3 hours ago Ned Pagliarulo Lead Editor post share post print email license The U.S. While the two treatments are constructed differently, they both use the same kind of engineered virus to deliver a replacement gene to the body’s muscles.

Therapies 159
article thumbnail

Dyadic International Rebrands as Dyadic Applied BioSolutions

The Pharma Data

For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. Our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution. The rebranding reflects our top priority: to deliver high-value input proteins at commercial scale.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

k kh,h,,h, jjgm gmm

Twist Bioscience

Human Comprehensive Exome Human Core Exome Human Methylome Panel Human RefSeq Panel Mitochondrial Panel Mouse Exome Panel Respiratory Virus Research Panel Comprehensive Viral Research Panel Twist's Whole Exome Library Preparation Workflow.

RNA 52
article thumbnail

Finding the right CDMO partner for cell line development

Drug Target Review

For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies. The first concern is microbial contamination. CDMOs must routinely test throughout CLD to ensure cell cultures are free of microbes.

article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 For additional information, please visit [link].

article thumbnail

COVID-19 nasal vaccine candidate effective at preventing disease transmission

The Pharma Data

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. Breathe in, exhale.

Vaccine 52
article thumbnail

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

The Pharma Data

05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. . MUNICH, Germany, Jan.